OmniScreen™ Cell Based Screening Service

Access our regular in vitro screening program for rapid and cost effective screening of over 500 cell lines


"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Pinpoint Your Opportunities for Therapeutic Intervention

To provide rapid information on the cytotoxicity and chemotherapeutic potential of your agent early in the drug development process, we have developed a cost effective approach to rapid screening, taking your lead compound to validated candidate.


OmniScreen, CrownBio’s Well Validated, Large-Scale Cell Panel Screening Platform

Regular, Cost-Effective Screening

OmniScreen is CrownBio’s global program for large-scale screening of client compounds against our proprietary collections of cancer cell lines, allowing you to:

  • Utilize multiple screening platforms including IncuCyte® ZOOM (real time) and Acumen eX3 (multiparameter)
  • Schedule any subpanel of 50 or more cell lines, with a screening run every 3 months
  • Select from quality cells STR verified and mycoplasma-proofed
  • Choose the models that best fit your needs with XenoBase® our curated, online database of cancer cell lines
  • Customize your study thanks to our flexible template designs
  • Quality control your data against standard of care agents
  • Obtain bioinformatics support throughout the study
  • Review your data in real time using a secure online client account

Focused Screening Panels

Our OmniScreen cancer cell line panels include:

  • OmniPanel™, a genomically diverse and growing collection of more than 500 cancer cell lines for drug response screening

  • XenoSelect™, a diverse oncogenic in vitro screening panel of more than 150 well validated cell lines with corresponding xenograft models ready for in vivo efficacy studies

  • RNAseq Panel, more than 170 in-house genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response.

  • PrimePanelTM, unique cell lines derived from our patient-derived xenograft (PDX) models.

Progress your Lead Compound to Validated Candidate with CrownBio’s Expanded OmniScreen™

Enroll by October 8th, 2018

OmniScreen is a reliable, large scale in vitro screen, which allows you to take advantage of CrownBio's quarterly revival of all 500+ cancer cell lines, providing you significant cost savings.

Highlights of OmniScreen:

  • High throughput screening of at least 50 cell lines per run to maximize your savings
  • Positive drug control and cell line revival costs are included as part of OmniScreen
  • Unique subpanels built from CrownBio’s proprietary menu of 500+ cancer cell lines
    • XenoSelect™ Panel of cell lines with paired xenograft models available to accelerate your transition to in vivo studies
    • RNAseq Panel of cell lines with in-house NGS data.
    • PrimePanel of unique cell lines derived from our patient derived xenograft (PDX) models.

  • Enhanced cell line growth data for improved screening quality including:
    • Validated seeding densities across multiple time points

Request OmniScreen Pricing

Quick Facts


  • AACR 2015 1038 - Cell-based Screening Identifes Gene Expression Signature Correlated with Sensitivity to PI3KmTOR Dual Inhibitor BEZ235
  • AACR 2014 3440 - Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to MEK Inhibitor Trametinib

Related Services

Blog Posts